title: Probability of cure in elderly Hodgkin's disease patients.
abstract: BACKGROUND
  Elderly Hodgkin's disease patients have a poor prognosis. The question arises whether these patients need aggressive treatment or a palliative strategy. So far, as a consequence of the scarcity of trials designed for them, useful information can be obtained only by retrospective analyses.
  
  
  METHODS
  We retrospectively studied clinical data from 567 patients recorded from 1982 to 1989 in the Piemonte Hodgkin's Disease Register (PHDR). The 65 patients over 65 years of age were compared to younger ones. We analyzed the role of disease independently of confounding variables, mainly inadequacy of staging and/or treatment, comorbidity and toxicity.
  
  
  RESULTS
  In the elderly comorbidity was as high as 35%. Forty elderly patients (60%) entered a suboptimal plan with a low degree of aggressivity, which was different from the usual PHDR protocol. Elderly patients also had a high proportion of subsequent protocol interruptions (25%). Chemotherapy dose intensity was negatively affected by advanced age (p < 0.01 after both 3 and 6 courses of chemotherapy). Toxic deaths were significantly higher in elderly patients than in younger ones (14% vs 1%; p < 0.05). CR rates, overall survival (OS), disease-specific survival (DSS) and event free survival (EFS) were all significantly influenced by age (p < 0.01). Relapse-free survival (RFS) in patients achieving CR did not differ according to age class (77% vs 60%; p = ns). RFS was better in elderly patients entering the PHDR protocols than in those following an alternative plan (75% vs 54%; p = 0.04); however, elderly patients treated according to PHDR guidelines showed a higher incidence of toxic deaths than those treated less aggressively (23% vs 8%). The two groups had similar EFS (36% vs 24%; p = ns).
  
  
  CONCLUSIONS
  Elderly patients who achieve CR can have good RFS and cure is possible, but the toxic cost of conventional strategies is unacceptable and selected strategies still must be found.
authors.affiliation: Divisione di Ematologia, Ospedale Molinette, Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Levis
authors.forename: L
authors.initials: L
authors.lastname: Depaoli
authors.forename: A
authors.initials: A
authors.lastname: Urgesi
authors.forename: M
authors.initials: M
authors.lastname: Bertini
authors.forename: L
authors.initials: L
authors.lastname: Orsucci
authors.forename: U
authors.initials: U
authors.lastname: Vitolo
authors.forename: G
authors.initials: G
authors.lastname: Buchi
authors.forename: A
authors.initials: A
authors.lastname: Gallamini
authors.forename: P
authors.initials: P
authors.lastname: Gavarotti
authors.forename: A
authors.initials: A
authors.lastname: Novarino
authors.forename: D
authors.initials: D
authors.lastname: Rota Scalabrini
authors.forename: U
authors.initials: U
authors.lastname: Mazza
authors.forename: A
authors.initials: A
authors.lastname: Pileri
authors.forename: G L
authors.initials: GL
authors.lastname: Sannazzari
authors.forename: L
authors.initials: L
authors.lastname: Resegotti
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D015993:Life Tables; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis